Sign in
Active, not recruitingNo phase

Safety and Efficacy of the Surpass Evolve Flow Diverter in Treating Intracranial Aneurysms

Key facts

Who runs it
Yibin Fang
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
150 people, planned
Started
29 Nov 2024
Ended
31 Dec 2025
Type of study
Observational
Treatments tested
  • Flow diverting
Record updated
13 December 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Age ≥ 18 years with a confirmed diagnosis of intracranial aneurysm
  • Imaging studies confirming suitability for Surpass Evolve Flow Diverter treatment
  • Aneurysms meeting flow diverter treatment indications (e.g., aneurysms larger than 4 mm)
  • At least six months of follow-up data available post-treatment

Who cannot take part

  • Patients with acutely ruptured aneurysms or significant bleeding
  • Patients with incomplete data or insufficient follow-up records

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Safety and Efficacy of the Surpass Evolve Flow Diverter in Treating Intracranial Aneurysms

The group in the trial

  • Surpass Evolve Flow Diverter

    Treatment: Flow diverting

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
13 December 2024